Showing Results for
From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-ReviewedBackground Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to...
From:PLoS ONE (Vol. 13, Issue 11) Peer-ReviewedRegulation of transcription is a key process in cellular homeostasis. It depends on regulators that either repress or stimulate the transcription of genes, therefore controlling different biological functions. The...
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by...
From:PLoS ONE (Vol. 14, Issue 4) Peer-ReviewedPurpose Epigenetic regulating proteins like histone methyltransferases produce variations in several functions, some of them associated with the generation of oncogenic processes. Mutations of genes involved in these...
From:PLoS ONE (Vol. 6, Issue 12) Peer-ReviewedThe p38 MAPK signaling pathway has been proposed as a critical mediator of the therapeutic effect of several antitumor agents, including cisplatin. Here, we found that sensitivity to cisplatin, in a system of 7...
From:PLoS ONE (Vol. 4, Issue 7) Peer-ReviewedResistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance...
Choose how you want to be alerted when new results for your search become available.
Subscribe to Gale's RSS feed to get content delivered to your favorite RSS aggregator. Copy and paste the URL below into your reader:
Tell us where to send the alert and how often you want to receive it